Texas Psychiatry. BE/BC Psychiatrists are invited to join a progressive mental health organization. Outstanding group of dedicated mental health professionals providing outpatient services to mainly t...
Clinicians and researchers from around the world attended this week's 8th International Forum on Mood and Anxiety disorders in Vienna, Austria to discuss the latest advances in the treatment of mood disorders. A wide range of topics were included in this year's programme, highlighting the position of IFMAD in the congress calendar as a forum for breaking news, original thinking and debate.
Lipocine Inc., a specialty pharmaceutical company that uses clinically validated proprietary technologies to address key unmet drug delivery and therapeutic needs, today announced the successful completion of a clinical study that establishes feasibility of the first once-a-day dosing product for Ziprasidone, a leading treatment for schizophrenia and bipolar disorder. - Schizophrenia affects 1% of the population and bipolar disorder affects 5.7M adults in the US*.
AstraZeneca today announced that the once-daily formulation SEROQUEL XR™ (quetiapine fumarate extended release tablets) and SEROQUEL® (quetiapine fumarate) have been approved via the Mutual Recognition Procedure for new indications in bipolar disorder. SEROQUEL XR and SEROQUEL have been approved for treatment of major depressive episodes in bipolar disorder. Additionally, SEROQUEL XR has been approved for treatment of moderate to severe manic episodes in bipolar disorder.
Repligen Corporation (Nasdaq: RGEN) announced that the Company has initiated a Phase 2b clinical trial to evaluate the use of RG2417, an oral formulation of uridine, in patients with bipolar depression. This Phase 2b study is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or placebo twice daily for eight weeks.
About 1.4 million hospitalizations in 2006 involved patients who were admitted for a mental illness, while another 7.1 million patients had a mental disorder in addition to the physical condition for which they were admitted, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The 8.5 million hospitalizations involving patients with mental illness represented about 22 percent of the overall 39.5 million hospitalizations in 2006.
A study carried out in the Institute of Neurosciences of the University of Granada (Spain) and the Mental Health Unit of the Hospital Neurotraumatológico of Jaen (Spain) has evaluated the quality of life of patients suffering from bipolar disorder (BD), in comparison with the general population, and which variables are connected with patients with a lower quality of life.
